European Journal of Clinical Pharmacology

, Volume 30, Issue 2, pp 225–230 | Cite as

Dose-dependent pharmacokinetics of dexamethasone

  • D. Loew
  • O. Schuster
  • E. H. Graul
Article

Summary

The dose dependency of the pharmacokinetics of dexamethasone and its influence on the endogenous secretion of cortisol has been studied in healthy females. The maximum plasma level occurred between 1.6 and 2.0 h after doses of 0.5–3.0 mg independent of the type of administration. AUC, distribution volume, plasma clearance and cmax did not increase in proportion to the dose but only by the factor of about 0.6–0.7 after the oral administration of 0.5–1.5 mg. Comparatively high values were reached after 3.0 mg i.m. This may be due to reduced bioavailability of the oral doses. Within the first 12 h after the administration of 0.5–3.0 mg, endogenous cortisol secretion was influenced independent of dose. However, the suppressive effect after 24 h was dose dependent and amounted to approximately 24% for 0.5 mg p. o., 62% for 1.5 mg p. o. and 90% for 3.0 mg i. m. In the case of administration every second day, the integral reduction within 24 h after the administration of 0.5 mg dexamethasone was 44 to 65% and for 1.5 mg between 59 and 62%.

Key words

dexamethasone pharmacokinetics dose dependancy suppression of cortisol healthy females 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Al-Habet S, Rogers HJ (1980) Pharmacokinetics of intravenous and oral prednisolone. Br J Clin Pharmacol 10: 503–508Google Scholar
  2. 2.
    Ballard PL, Carter JP, Graham BS, Baxter JD (1975) A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J Clin Endocrinol Metab 41: 290Google Scholar
  3. 3.
    Baxter JD, Forsham PH (1972) Tissue effects of glucocorticoids. Am J Med 53: 573Google Scholar
  4. 4.
    Bozler G, van Rossum (1982) Data analysis and evaluation techniques during drug development. Fischer, Stuttgart New York, p 207Google Scholar
  5. 5.
    Daughaday WH (1985) Binding of corticosteroids by plasma proteins. Arch Intern Med 101: 286–290Google Scholar
  6. 6.
    Daughaday WH, Kozak I (1958) Binding of corticosteroids by plasma proteins IV. The electrophoretic demonstration of corticosteroid binding globulin. J Clin Invest 37: 519–523Google Scholar
  7. 7.
    Duggan DE, Yeh KC, Matalia N, Ditzier CA, MacMahon FG (1975) Bioavailability of oral dexamethasone. Clin Pharmacol Ther 18: 205–209Google Scholar
  8. 8.
    Fellier H, Gleispach H, Esterbauer H (1977) Bindung von Cortisol, Fluocortolon und Difluocortolon an Humanplasmaproteine. J Clin Chem Clin Biochem 15: 545–548Google Scholar
  9. 9.
    Florini JR, Buyske DA (1961) Plasma protein binding of triamcinolone-H3 and Hydrocortisone-4-C14. J Biol Chem 236: 247Google Scholar
  10. 10.
    Haack D, Günther D, Kunkel G, Lichtwald K, Täuber U, Vecsei P (1981) Radioimmunologische Bestimmung von synthetischen Glukokortikoiden. Atemw Lungenkrh 7: 283–289Google Scholar
  11. 11.
    Martin IE, Tanner RJN, Clark TJH, Cochrane GM (1973) Absorption and metabolism of orally administered beclomethasone dipopionate. Clin Pharmacol Ther 15: 267–275Google Scholar
  12. 12.
    Miyabo S, Nakamura T, Kuwazima S, Kishida S (1981) A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man. Eur J Clin Pharmacol 20 [4]: 277–282Google Scholar
  13. 13.
    Möllmann H, Brauwers H, Wagner H, Bigalke C, Rohdewald P, Straub H (1980) Vergleichende Untersuchungen über den Einfluß verschiedener triamcinolonhaltiger Kristallsuspensionen auf den Plasmacortisolspiegel. Therapiewoche 30: 1068–1084Google Scholar
  14. 14.
    Peets EA, Straub M, Symchowicz S (1969) Plasma binding of beta-methasone-3H, Dexamethasone-3H and cortisol-14C — a comparative study. Biochem Pharmacol 18: 1655–1663Google Scholar
  15. 15.
    Pickup HE, Lowe JR, Leatham PA, Rhind VM, Wright V, Downie WW (1977) Dose dependent pharmacokinetics of prednisolone. Eur J Clin Pharmacol 12: 213–219Google Scholar
  16. 16.
    Tanner A, Bochner F, Caffin J, Haddiday J, Powell L (1979) Dose-dependent prednisolone kinetics. Clin Pharmacol Ther 25: 571–578Google Scholar
  17. 17.
    Täuber U, Haack D, Nieuweboer B, Kloss G, Vecsei P, Wendt H (1984) The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. Clin Pharmacol Ther Toxicol 22: 48–55Google Scholar
  18. 18.
    Toothaker RD, Welling PG (1982) Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression. J Pharmacokinet Biopharmaceut 10 [2]: 147–156Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • D. Loew
    • 1
  • O. Schuster
    • 1
  • E. H. Graul
    • 1
  1. 1.MECICEF-Institut (International Center for Environmental Sciences and Future Research) Marburg/LahnGermany

Personalised recommendations